2026-04-14T15:14:00Zhttps://uvadoc.uva.es/oai/request

oai:uvadoc.uva.es:10324/656092025-09-10T12:16:41Zcom_10324_1145com_10324_931com_10324_894col_10324_1254

Barceló, Antonia Peña, Mónica de la Ayllón, Olga Vega Agapito, María Victoria Piérola, Javier Pérez, Gerardo González Martínez, Constancio Alonso, Alberto Agustí, Alvar GN 2024-02-02T23:27:13Z 2024-02-02T23:27:13Z 2009 Respiration, octubre 2009, vol. 77, p.85-90 https://uvadoc.uva.es/handle/10324/65609 10.1159/000165630 85 90 77 Cardiovascular (CV) diseases are a leading cause of mortality and they are frequent in patients with the obstructive sleep apnea syndrome (OSAS). Objectives: In this study we investigated if OSAS influences CV function independently of other CV risk factors frequently present in these patients (e.g. obesity, high blood pressure). Methods: We compared plasma markers of endothelial dysfunction, asymmetric dimethylarginine (ADMA) and endothelin-1 (ET- 1), and atherosclerosis progression (soluble fraction of the CD40 ligand, sCD40L) in OSAS patients with (n = 23) and without (n = 18) concurrent CV risk factors, as well as in healthy subjects (n = 23). Results: Plasma ADMA (p ! 0.01) and sCD40L (p ! 0.05) were abnormally increased in patients with OSAS versus healthy controls, but they were not influenced by the presence or absence of CV risk factors in OSAS. ET-1 levels were not different between the three groups of subjects studied. Conclusions: OSAS is associated with endothelial injury and atherosclerosis progression independently of other CV risk factors. eng info:eu-repo/semantics/restrictedAccess Karger Increased Plasma Levels of Asymmetric Dimethylarginine and Soluble CD40 Ligand in Patients with Sleep Apnea info:eu-repo/semantics/article